Objective Beraprost was developed as the first oral prostacyclin analog to treat patients with pulmonary arterial hypertension (PAH). Although this drug demonstrates improvements in the patient's exercise capacity and symptoms, it carries a weak recommendation in the PAH evidence-based treatment algorithm due to a lack of durability of effects. However, this therapy remains a major treatment method in Japan due to its availability and inexpensive cost. The purpose of this study was to elucidate whether this drug exhibits durable effects on sustained overall survival. Methods A comparison of survival benefits was completed among patients undergoing treatment with beraprost (n=35) or conventional therapy (n=44). In addition, the estimated survival calculated using the equation developed by the National Institutes of Health Registry was used for the analysis. Results Although no significant differences were observed between the two groups using the Kaplan-Meier survival curve, a statistical difference was observed between the patients receiving high-dose beraprost therapy (>120 μg) and those receiving conventional therapy (5-and 10-year survival: 71.1% and 49.4% vs. 37.7% and 21.2%, respectively; p=0.0466). Moreover, the cumulative survival rates in the patients receiving beraprost were slightly better than the estimated survival rates. In the PAH patients with connective tissue diseases, a tendency towards better survival outcomes was observed in the group treated with beraprost. Conclusion This study suggests the survival benefits of high-dose beraprost therapy for patients with PAH. The retrospective nature of this study, however, makes it difficult to conclude definitively that beraprost exerts significant beneficial effects on survival.
Introduction
Pulmonary arterial hypertension (PAH) is characterized by the obstruction of blood flow in resistant pulmonary arteries due to vascular remodeling composed of hyperproliferative cells, including pulmonary artery endothelial cells (ECs) and/or smooth muscle cells (SMCs) and excess deposition of the extracellular matrix (1, 2) . These dysfunctional cells ultimately induce signaling imbalances between vasoconstrictive (e.g., endothelin) and vasodilatory (e.g., prostacyclin and nitric oxide) compounds (3) .
Three classes of drugs are currently used to treat PAH, including prostacyclin analogues [e.g., epoprostenol, beraprost, treprostinil and iloprost (treprostinil and iloprost are approved outside of Japan)], endothelin receptor antagonists (ERAs) (e.g., ambrisentan and bosentan) and phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil and tadalafil) (4) . The availability and convenience of oral ERAs and PDE5 inhibitors have recently made these drugs more common in the treatment of PAH after being introduced in Japan in 2005. Indeed, these oral medications have been found to significantly improve survival in Japanese patients with idiopathic and heritable PAH in comparison to other therapies, albeit in a single-center, uncontrolled study (5) .
Conventional therapies, such as anticoagulants, calcium channel blockers, diuretics, digoxin and supplemental oxygen, were the only treatments for patients with PAH before the introduction of beraprost in 1992. Beraprost was developed as the first orally active and chemically stable prostacyclin analog and has been available for the treatment of PAH in Japan since 1992. Beraprost demonstrated improvements in the exercise capacity and symptoms of patients in a randomized, double-blind study using the maximum dose (80 μg four times daily) or a placebo for short-term durations (6) . However, another long-term randomized controlled trial showed that there are no beneficial effects of oral beraprost on pulmonary hemodynamics or exercise capacity at nine or 12 months (7). This indicates that oral beraprost may have a lack of durability of effects (8) . Therefore, this drug carries a weak recommendation in the PAH evidencebased treatment algorithm (4) , and the introduction of beraprost is limited to Japan and Korea (9) . In fact, oral beraprost was the first-line therapy for Japanese PAH patients until the approval of ERAs and PDE5 inhibitors in 2005. After the introduction of these drugs, beraprost was no longer the only oral therapy, and since then, the use of this drug has been gradually declining. However, oral beraprost therapy remains a major treatment for patients with PAH in Japan due to its availability and inexpensive cost. In this report, we address whether oral therapy with beraprost exhibits durable effects on sustained overall survival.
We herein investigate the cumulative survival in PAH patients treated with beraprost in comparison to that observed in historical controls treated with conventional therapy using the estimated survival calculated with the equation developed by the National Institutes of Health (NIH) Registry (10).
Materials and Methods

Study subjects
From June 1983 to October 2012, 112 patients older than 15 years of age with PAH were treated at Chiba University Hospital. In all patients, right heart catheterization (RHC) was used to make the diagnosis of PAH by confirming the presence of pulmonary hypertension based on a documented mean pulmonary arterial pressure of " 25 mmHg and a pulmonary capillary wedge pressure or a left ventricular enddiastolic pressure of ! 15 mmHg. The study inclusion criteria were Group 1.1 to 1.4 on the current Dana Point classification system (11) . The study exclusion criteria were the same as those described previously (5) .
According to Japanese legislation, informed consent is not required for retrospective collection of data corresponding to current practice. However, the database was anonymized and complied with the restrictive requirements of the Ministry of Health, Labour and Welfare with respect to privacy, information technology and civil rights in Japan. The Ethics Committees of Chiba University Hospital approved the study protocol.
Efficacy measurements
A fundamental flow diagram of PH therapies is shown in Fig. 1 . Almost all patients treated with conventional therapies were diagnosed before the introduction of beraprost. Following the approval of this drug, oral beraprost has been the first-line therapy for Japanese PAH patients until the introduction of ERAs and PDE5 inhibitors. After these approvals, their use was prevalent in Japan and, depending on the symptom and hemodynamic aggravation, some of the patients treated with beraprost received second approved PAH therapies including ERAs and PDE5 inhibitors. Of the 112 patients, thirty-three patients treated with ERAs and/or PDE5 inhibitors as a first-line therapy and/or with epoprostenol were excluded. The others were retrospectively divided into two groups: those treated with beraprost (n=35) and those treated with conventional therapy, including anticoagulants, calcium channel blockers, diuretics, digoxin and supplemental oxygen (n=44). Of all patients treated with beraprost, five patients (14.3%) suffered side effects within one week of the administration of this drug, including pressure decrease (n=2), flushing and dyspnea (n=1), flushing (n=1) and diarrhea (n=1). All patients in the beraprost group finally tolerated at least 60 mg/day of beraprost by reducing the dose of this drug or splitting the medication of the dose over the course of the day. In this analysis, the most current hemodynamic data were confirmed before treatment was investigated. For more detailed analyses, the subjects were divided into subgroups with regard to the type of PAH. The survival status of all patients was followed on a yearly basis and at the end of the study. Five of the 112 patients were lost to follow-up. In patients treated with conventional therapies, the date of the diagnosis with RHC was considered as the initial point in determining the survival period because conventional therapies were ordinarily started before the diagnosis with RHC. Therefore, to determine the survival period for investigating the effects of the drug, the date of the diagnosis with RHC was also selected as the initial point in the beraprost group. The survival rates were calculated according to subgroup using Kaplan-Meier estimates. The baseline demographic and hemodynamic data were investigated according to subgroup.
The estimated survival was calculated using the NIH Registry equation (10) . The baseline clinical hemodynamics, including the mean right atrial pressure (mRAP), the mean pulmonary artery pressure (mPAP) and the cardiac index (CI), were substituted for estimated survival in the equation. D'Alonzo et al. previously described the details of the equation (10) . The estimated survival rates were calculated at one, three and five years.
Statistical analysis
The data were analyzed using the JMP 9.0.0 (Japanese version, SAS Institute Inc., Tokyo, Japan) and Excel-Toukei inhibitors as a first-line therapy and/or with epoprostenol were excluded in this study. Almost all patients treated with conventional therapies, such as anticoagulants, calcium channel blockers, diuretics, digoxin and supplemental oxygen, were diagnosed before the introduction of beraprost. Since the approval of this drug, oral beraprost has been the first-line therapy for Japanese PAH patients until the introduction of ERAs and PDE5 inhibitors. After these approvals, depending on the symptoms and degree of hemodynamic aggravation, some of the patients treated with beraprost received second approved PAH therapies including ERAs and PDE5 inhibitors. ERAs: endothelin receptor antagonists, PDE5 inhibitors: phosphodiesterase type 5 inhibitors 2010 software programs (Social Survey Research Information Co., Ltd., Tokyo, Japan). The baseline data were compared using unpaired Student's t-tests. The survival was estimated using the Kaplan-Meier method. Univariate and multivariate cox proportional hazards models were used to investigate the independent effects of the factors on survival. A p value of 0.05 was considered to be statistically significant. Further details of the statistical method used in this study have been previously described (5) .
Results
Baseline characteristics
The mean patient age in the group treated with beraprost and the group treated with conventional therapy were 52.5± 16.1 years (range: 16 to 75) and 44.1±14.8 years (range: 20 to 72) with a 29:6 and 36:8 female to male ratio, respectively. Twenty-five of 35 PAH patients treated with beraprost received a high dose of this drug (>120 μg). Thirty-seven patients (46.8%) were identified as having idiopathic and heritable PAH, and 30 patients (38.0%) were identified as having PAH associated with connective tissue diseases. The patients were followed for a mean period of 4.92±5.13 and 4.72±5.56 years and a median of 3.41 years (range: 0.23 to 121.70) and 2.73 years (range: 0.05 to 22.68), respectively. The mPAP and the mean pulmonary vascular resistance (PVR) were 45.8±10.0 and 50.5±14.8 mmHg and 798± 300.6 and 1,033±608 dyn·s·cm -5 , respectively.
Survival outcomes of patients treated with beraprost compared with patients treated with conventional therapy
To elucidate the absolute benefits of beraprost for the survival of Japanese patients with PAH, an analysis was performed to compare the outcomes of patients treated with beraprost (n=35) and patients treated with conventional therapies (n=44) ( Table 1) . Of the patients treated with beraprost, 88.6% and 48.6% received short-acting and longacting beraprost, respectively. Moreover, the patients received the higher dose of beraprost if they were tolerant. Of the patients under follow-up, depending on symptom and hemodynamic aggravation, 34.2% and 37.1% received a second approved PAH therapy at one and three years, respectively (Table 1) . In most cases, the patient received one additional therapy, including bosentan in nine and sildenafil in nine of the 35 patients (Table 1) .
Although no significant differences were observed between the patients treated with beraprost and those treated with conventional therapy in the Kaplan-Meier survival curve (5-and 10-year survival: 59.5% and 43.4% vs. 37.7% and 21.2%, respectively; p=0.0885) (Fig. 2) , a statistical difference was observed between the patients treated with highdose beraprost (>120 μg) and those treated with conven- Bosentan, n (%) Ambrisentan, n (%) Sildenafil, n (%) Tadalafil, n (%) Epoprostenol, n (%) Oral beraprost, n (%) Short-acting, n (%) Long-acting, n (%) tional therapy (5-and 10-year survival: 71.1% and 49.4% vs. 37.7% and 21.2%, respectively; p=0.0466) (Fig. 3 ). In addition, the patients with idiopathic and heritable PAH treated with beraprost (n=14) did not exhibit better survival outcomes than those treated with conventional therapy (n= 23) (Table 1) (5-and 10-year survival: 51.4% and 27.4% vs. 37.5% and 18.7%, respectively; p=0.7349) (Fig. 4) . However, among the PAH patients with connective tissue diseases (Table 1) , those treated with beraprost were likely to exhibit a better survival tendency than those treated with conventional therapy (5-and 10-year survival: 57.5% and 47.9% vs. 16.7% and 16.7%, respectively; p=0.0572) (Fig. 5) .
A univariate cox proportional hazard analysis of the patients treated with high-dose beraprost (>120 μg) demonstrated that PVR and the use of high-dose beraprost therapy were not associated with cumulative survival. However, only PVR was found to be a statistically significant predictor of survival in the multivariate analysis of these patients. Unfortunately, the use of high-dose beraprost therapy was not found to be an independent predictor of superior outcomes (Table 2) .
Cumulative survival of patients treated with beraprost in comparison to the estimated survival calculated using the NIH Registry equation
To investigate the survival benefits of beraprost in patients with PAH, the cumulative survival of these patients was compared to the estimated survival which was calculated using the equation developed by the NIH Registry. Among the PAH patients treated with beraprost, the cumulative survival rates at one, three and five years were 80.0%, 66.9% and 59.5%, respectively, while among the same patients, the estimated survival rates were 80.2%, 63.7% and 53.4%, respectively (Table 3) . These results indicate that there was a trend toward slightly superior survival in the PAH patients treated 
Discussion
This study demonstrated that there are possible cumulative survival benefits in PAH patients treated with high-dose beraprost (>120 μg) therapy in comparison to those treated with conventional therapy (Fig. 3) , although high-dose beraprost therapy is not an independent predictor of superior outcomes ( Table 2) . In this study, PAH patients with connective tissue diseases treated with beraprost tended to have better survival outcomes than those treated with conventional therapy. In multiple sub-analyses, however, valid conclusions could not be made due to the small sample size. The PAH patients treated with beraprost exhibited a trend toward slightly superior survival at one, three and five years compared to the estimated survival calculated using the NIH equation. However, the NIH equation may underestimate the prognosis because of improved survival data which were demonstrated in recent registry studies (12) . Moreover, the previous report suggested that earlier diagnosis of this disease has been more frequently achieved possibly based on the increased recognition of PAH by doctors (5) . The recent improved patient care, including doctor recognition of the disease, may have bearing upon the results in the beraprost treatments.
Patients treated with beraprost had significantly less serious PVR alteration and were older (Table 1) . Furthermore, the PVR was determined as a predictor of survival in the multivariate analysis of these patients (Table 2) . Therefore, the fact that the beraprost group actually had less severe disease makes it difficult to attribute the superior outcome to the beraprost treatment (Fig. 2) . Moreover, effects of a second approved PAH therapy on the superior outcome in patients treated with beraprost were undeniable.
Both an imbalance between pulmonary artery vasoconstriction and vasodilatation and the presence of pulmonary arterial remodeling with marked proliferation of pulmonary artery ECs and SMCs are thought to contribute to the pathophysiology of PAH (13-15), thus resulting in obstruction and pressure elevation of the pulmonary arteries. In the current study, a tendency towards better survival outcomes was observed in the PAH patients with connective tissue diseases treated with beraprost, suggesting that this vasodilative drug may function more effectively in this type of PAH than in others. Indeed, a greater vasospastic predisposition of the pulmonary arteries has been suggested to be present in PAH patients with connective tissue diseases compared to that observed in other types of PAH patients, as 83% of patients with PAH secondary to connective tissue diseases have Raynaud's phenomenon (in comparison to 10-14% of patients with idiopathic PAH) (16) . Among patients with PAH secondary to connective tissue diseases, a vasoconstrictive predisposition of the pulmonary arteries may contribute to the pathophysiology of PAH more so than the pulmonary arterial remodeling with hyperproliferative cells. However, it remains unknown whether these patients with a vasospastic predisposition of the pulmonary arteries are really vasoreactive. In particular, it is likely that vasoreactivity in PAH patients with systemic sclerosis (SSc) is abnormal despite the presence of Raynaud's phenomenon (17) . Therefore, such a predisposition is not sufficient to explain our results. The current study suggests that only high-dose beraprost therapy tends to have a role on prolonging the overall survival in PAH patients (Fig. 3) . Furthermore, in a randomized controlled trial with a total of 116 PAH patients, the patients treated with the maximum tolerated dose of beraprost (120 μg) demonstrated improvements in their exercise capacity and decreased disease progression at six months (7). Randomized controlled trials using the maximum tolerated dose in Japanese patients may be able to show sustained effects in PAH patients. Indeed, a randomized controlled doseresponse study of this drug is currently underway (18) .
In the current study, 17 patients received long-acting beraprost, which was developed to maintain the plasma concentration of an active prostacyclin derivative. An open-label multicenter clinical trial of this long-acting drug demonstrated improved exercise capacity and hemodynamics in PAH patients treated with the drug for 12 weeks (19) . This prostacyclin derivative can deliver a high dose of beraprost sodium and achieve a prolonged and continuous plasma concentration of beraprost sodium using twice-daily administration (19) . Although the current study suggested the dosedependent effects of beraprost, it remains unknown whether long-acting beraprost exerts prolonged effects on survival over long-term observation periods. The effects of longacting beraprost need to be further examined in a long-term trial.
In the current study, over the 28-year time period, the practices of our hospital have evolved. Therefore, the results of the cardiac ultrasound, brain natriuretic peptide (BNP) tests, and six minute walk distance (6MWD) tests were not obtained as consistently in the past as they have been in recent years. For this reason, survival benefits were only evaluated by treatment method, instead of comparing other indices.
The current study suggests that oral therapy with beraprost possibly displays durable effects on overall survival, more so than conventional therapy, especially in some populations of PAH patients. Because the study presented here is an observational study performed at a single center with a small sample size, the results are limited. Moreover, the decision to treat all patients receiving beraprost as one group, despite some patients receiving a second approved PAH therapy, is a limitation that has some influence on all of the clinical implications herein presented These limitations make it difficult to definitively conclude that beraprost exerts significant beneficial effects on patient survival. Although the advantages of this drug appeared to be minimal, the present study suggests that there are beneficial effects of treatment with high-dose beraprost on overall patient survival. In Japan, many PAH patients continue to be treated with oral beraprost due to its availability and inexpensive cost. Therefore, the effects of high-dose beraprost therapy need to be further investigated in a large confirmatory long-term trial. Financial Support
